Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Asset disposition
CC transcript
Quarterly results
Appointed director

Viracta Therapeutics, Inc. (VIRX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/04/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "FORM 8-K",
"Viracta Therapeutics to Host R&D Day Highlighting Nana-val in Epstein-Barr Virus -Associated Cancers",
"Corporate Presentation"
08/18/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
08/18/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
08/16/2023 3 Cohen Darrel P. (Chief Medical Officer) has filed a Form 3 on Viracta Therapeutics, Inc.
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/14/2023 8-K Quarterly results
Docs: "Viracta Therapeutics, Inc. Selected Balance Sheet Highlights June 30, December 31, 2023 2022 Cash, cash equivalents and short-term investments $ 72,867 $ 91,043 Total assets $ 76,859 $ 95,991 Total liabilities $ 36,077 $ 34,888 Stockholders' equity $ 40,782 $ 61,103 Viracta Therapeutics, Inc. Condensed Consolidated Statement of Operations and Comprehensive Loss Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Operating expenses: Research and development $ 8,197 $ 6,324 $ 15,804 $ 12,420 General and administrative 4,253 4,181 8,853 8,517 Total operating expenses 12,450 10,505 24,657 20,937 Loss from operations Total other expense Net loss Unrealized gain on short-term investments — 63 — Comprehensive loss Net loss per share, basic and diluted $ $ $ $ Weight..."
08/07/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Head of Investor Relations"
06/09/2023 4 Simon Barry J. (Director) has filed a Form 4 on Viracta Therapeutics, Inc.
Txns: Granted 40,000 options to buy @ $1.5, valued at $60k
06/09/2023 4 Rubino Stephen (Director) has filed a Form 4 on Viracta Therapeutics, Inc.
Txns: Granted 40,000 options to buy @ $1.5, valued at $60k
06/09/2023 4 ROYSTON IVOR (Director) has filed a Form 4 on Viracta Therapeutics, Inc.
Txns: Granted 40,000 options to buy @ $1.5, valued at $60k
06/09/2023 4 Pomerantz Roger (Director) has filed a Form 4 on Viracta Therapeutics, Inc.
Txns: Granted 40,000 options to buy @ $1.5, valued at $60k
06/09/2023 4 Murphy Samuel Lafayette (Director) has filed a Form 4 on Viracta Therapeutics, Inc.
Txns: Granted 40,000 options to buy @ $1.5, valued at $60k
06/09/2023 4 DARCY THOMAS E (Director) has filed a Form 4 on Viracta Therapeutics, Inc.
Txns: Granted 40,000 options to buy @ $1.5, valued at $60k
06/09/2023 4 Chung Jane (Director) has filed a Form 4 on Viracta Therapeutics, Inc.
Txns: Granted 40,000 options to buy @ $1.5, valued at $60k
06/09/2023 4 Borellini Flavia (Director) has filed a Form 4 on Viracta Therapeutics, Inc.
Txns: Granted 40,000 options to buy @ $1.5, valued at $60k
06/09/2023 4 Barlow Jane F (Director) has filed a Form 4 on Viracta Therapeutics, Inc.
Txns: Granted 40,000 options to buy @ $1.5, valued at $60k
06/09/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/26/2023 4 ROYSTON IVOR (Director) has filed a Form 4 on Viracta Therapeutics, Inc.
Txns: Exercised 25,219 restricted stock units @ $0
05/26/2023 4 Pomerantz Roger (Director) has filed a Form 4 on Viracta Therapeutics, Inc.
Txns: Exercised 9,035 restricted stock units @ $0
05/26/2023 4 Chevallard Daniel R. (CFO and COO) has filed a Form 4 on Viracta Therapeutics, Inc.
Txns: Sold 3,635 shares @ $1.4196, valued at $5.2k
Exercised 6,889 restricted stock units @ $0
05/26/2023 144 Form 144 - Report of proposed sale of securities:
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/08/2023 8-K Quarterly results
Docs: "-- Financial tables attached – Viracta Therapeutics, Inc. Selected Balance Sheet Highlights March 31, December 31, 2023 2022 Cash, cash equivalents and short-term investments $ 80,332 $ 91,043 Total assets $ 85,781 $ 95,991 Total liabilities $ 34,668 $ 34,888 Stockholders' equity $ 51,113 $ 61,103 Viracta Therapeutics, Inc. Condensed Consolidated Statement of Operations and Comprehensive Loss Three Months Ended March 31, 2023 2022 Operating expenses: Research and development $ 7,607 $ 6,096 General and administrative 4,600 4,336 Total operating expenses 12,207 10,432 Loss from operations Total other expense Net loss Unrealized gain on short-term investments 91 — Comprehensive loss Net loss per share, basic and diluted $ $ Weighted-average common shares outstanding, basic and diluted 3..."
05/05/2023 8-K/A Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "8-K/A",
"CONSULTING AGREEMENT This consulting agreement is made by and between VIRACTA THERAPEUTICS, INC., having a place of business at 2533 South Coast Hwy 101, Suite 210, Cardiff, CA 92007 USA, together with its affiliates and Lisa Rojkjaer, M.D., an individual with a place of business at [***] , effective on the 5th day of May, 2023 at 4:59pm PDT for the purpose of setting forth the exclusive terms and conditions by which Company will acquire Consultant's services on a temporary basis. 1. WORK AND PAYMENT. Attached to this Agreement as is a project assignment describing the work Consultant will perform . This Project Assignment, and any future Project Assignment, will be subject to the terms and conditions of this Agreement and will set forth at a minimum the following terms: Consultant's rate ..."
05/02/2023 8-K Quarterly results
04/27/2023 ARS Form ARS - Annual Report to Security Holders:
04/27/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/31/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/17/2023 4 Rothera Mark (President and CEO) has filed a Form 4 on Viracta Therapeutics, Inc.
Txns: Granted 400,000 options to buy @ $1.65, valued at $660k
03/17/2023 4 Rojkjaer Lisa (Chief Medical Officer) has filed a Form 4 on Viracta Therapeutics, Inc.
Txns: Granted 150,000 options to buy @ $1.65, valued at $247.5k
03/17/2023 4 Chevallard Daniel R. (CFO and COO) has filed a Form 4 on Viracta Therapeutics, Inc.
Txns: Granted 200,000 options to buy @ $1.65, valued at $330k
03/14/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/14/2023 10-K Annual Report for the period ended December 31, 2022
03/13/2023 8-K Quarterly results
Docs: "Viracta Therapeutics, Inc. Selected Balance Sheet Highlights December 31, 2022 2021 Cash, cash equivalents and short-term investments $ 91,043 $ 103,554 Total assets $ 95,991 $ 108,552 Total liabilities $ 34,888 $ 14,181stockholders' equity $ 61,103 $ 94,371 Viracta Therapeutics, Inc. Condensed Consolidated Statement of Operations and Comprehensive Loss Three Months Ended December 31, Year Ended December 31, 2022 2021 2022 2021 Operating expenses: Research and development $ 6,703 $ 7,303 $ 26,262 $ 23,861 Purchased and acquired in-process research and development — — — 88,478 General and administrative 4,871 4,015 24,327 15,437 Total operating expenses 11,574 11,318 50,589 127,776 Gain on Royalty Purchase Agreement — — — 13,500 Loss from operations Total other income 1,248 1,392 Net loss..."
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy